Seeking Alpha

RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3...

RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3 clinical trial of NeuVax, a cancer immunotherapy targeted for breast cancer patients not eligible for other treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)